Moderna, Merck cancer vaccine with Keytruda improved survival in trial
Moderna and Merck released more positive three-year data Monday on their experimental vaccine, given to patients with the most deadly form of skin cancer in combination with the therapy Keytruda. The vaccine together with Merck’s Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a deadly form of skin cancer. … Read more